clinical trial · NCT05727657
Satralizumab in Aneurysmal Subarachnoid Hemorrhage
Aneurysmal Subarachnoid HemorrhageDelayed Cerebral IschemiaSatralizumab
brief summary
In this study, satralizumab will be administered to see whether satralizumab is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.
started
Jun 1, 2024
primary completion
Jun 24, 2024
completion
Jun 24, 2024
last updated
Mar 4, 2025
detailed description
SASH is a prospective single-arm, single-center, open-label Phase 1 trial of satralizumab 120mg subcutaneous Day 0 and Day 14 in subjects with Hunt Hess grade 1-3, Fisher score 3 aneurysmal subarachnoid hemorrhage and an external ventricular drain or lumbar drain. The trial is designed to demonstrate safety and to detect a signal that satralizumab prevents delayed cerebral ischemia in these patients.
official title
A Phase 1 Clinical Trial of Satralizumab as a Treatment for Aneurysmal Subarachnoid Hemorrhage
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol